Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)

China · Delayed Price · Currency is CNY

7.80

-0.16 (-2.01%)

Oct 22, 2026, 4:00 PM EDT

Market Cap	17.41B -28.4%
Revenue (ttm)	4.06B -14.2%
Net Income	490.05M -47.6%
EPS	0.22 -47.3%
Shares Out	2.23B
PE Ratio	35.43
Forward PE	19.02
Dividend	0.17 (2.22%)
Ex-Dividend Date	Apr 29, 2026

Volume	8,790,600
Open	7.95
Previous Close	7.96
Day's Range	7.79 - 7.98
52-Week Range	7.69 - 12.90
Beta	0.02
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 23, 2026

About SHE:301301

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. It offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxychol... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2010

Employees 3,126

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 301301

Full Company Profile

Financial Performance

In 2025, SHE:301301's revenue was 4.62 billion, a decrease of -19.83% compared to the previous year's 5.76 billion. Earnings were 769.01 million, a decrease of -45.08%.

Financial Statements